The cutaneous lupus erythematosus (CLE) market is projected to expand at an 8% compound annual growth rate through 2036, driven by increased disease awareness, better diagnostics, and a focus on autoimmune disorders. New targeted therapies and biologics from companies like Biogen, Amgen, and AstraZeneca are broadening treatment options, with key drugs such as Litifilimab and Daxdilimab advancing in clinical trials. The U.S. leads the market, holding 60% of diagnosed cases, and antimalarials currently dominate treatment revenue. These emerging therapies are expected to transform patient care and market dynamics in the coming decade.
Biogen Inc. announced the appointment of Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of legal and strategic leadership in the biopharmaceutical industry, having held senior roles at Spur The...
The LEADER study found that nearly 83% of early Alzheimer's patients remained stable or improved while on LEQEMBI treatment for an average of 17 months, consistent across demographics and genetic profiles. LEQEMBI targets amyloid beta to slow cogniti...
Biogen announced positive Phase 2 results for diranersen, an antisense therapy targeting tau protein in early Alzheimer's disease. The study showed meaningful clinical benefits, including slowing cognitive decline by up to 50% on some measures, and r...
The FDA has approved LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating treatment of early Alzheimer's disease, allowing at-home dosing. This new form offers a convenient alternative to intravenous infusions, providing flexibility for...
Biogen's stock received an upgrade as investors anticipate the company's upcoming announcement of detailed data from its Phase 2 study on an experimental Alzheimer's drug. This data release is significant because it could impact the future of Alzheim...
